In a nutshell In this report, the European Society for Medical Oncology (ESMO) updated recommendations for treating metastatic (spread to other organs) colorectal cancer. Some background Colorectal cancer is one of the most common cancers diagnosed in Europe. Over the last decade in particular, the clinical outcome for patients with metastatic...
Read More
In a nutshell This study examined the effects of enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC) that has spread to the lungs and/or liver. Researchers reported that enzalutamide is safe and effective for men with mCRPC affecting the lung or liver. Some background When prostate cancer spreads outside of...
Read MoreIn a nutshell This review compared the effectiveness of talimogene laherparepvec (Imlygic) with ipilimumab (Yervoy) and vemurafenib (Zelboraf) in the treatment of metastatic (spread to other organs) melanoma. Researchers concluded that talimogene laherparepvec overall survival is at least as good as with ipilimumab and vemurafenib. Some background...
Read More
In a nutshell This study examined predictors of survival for cancer patients with spinal bone metastases. Authors reported that stable and unstable spinal bone metastases had similar survival rates. However, factors predictive of survival were different between groups. Some background When cancer spreads outside of the breast (known as...
Read More
In a nutshell This study investigated whether the neutrophil-lymphocyte (NLR; types of white blood cells) ratio is an effective predictor of ipilimumab (Yervoy) response in metastatic (spread to other parts of the body) melanoma patients. Researchers suggested that the NLR is strongly associated with the outcome of patients treated with...
Read More
In a nutshell This review examined the safety and effectiveness of dabrafenib (Tafinlar) and trametinib (Mekinist) for inoperable metastatic melanoma. Researchers concluded that this combined treatment is an important therapy option for patients with metastatic melanoma. Some background Some melanoma patients have a mutation...
Read More
In a nutshell This study aimed to assess whether surgery is beneficial for patients with advanced stage 4 NSCLC that has spread to other parts of the body. The authors concluded that for these patients, surgery resulted in longer survival time compared to those who did not undergo surgery. Some background For many patients with non-small cell lung...
Read MoreIn a nutshell This study examined treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) progressing after treatment with abiraterone acetate (Zytiga). Chemotherapy with docetaxel (Taxotere) was the most common subsequent therapy. Authors concluded that patients with mCRPC who progress after AA may still benefit from subsequent...
Read More
In a nutshell This phase 2 trial recruiting in Houston, Texas (US) aims to compare the effect of having a liver tumor surgically removed along with chemotherapy to chemotherapy alone in patients whose colorectal cancer has spread to their liver and lungs. The main outcome to be measured is overall survival (time from treatment until death from any...
Read More
In a nutshell This study examined the link between circulating tumor cells (CTCs) and treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Authors reported better survival outcomes for mCRPC patients with a significant decline in CTC count during treatment. Some background Metastatic castration-resistant prostate...
Read More
In a nutshell This study investigated the association between the tumor side and cetuximab (Erbitux) effectiveness in metastatic (spread to other parts of the body) colorectal cancer. Researchers reported that cetuximab was more effective in left-sided tumors. Some background Left and right- sided colorectal cancer have different...
Read MoreIn a nutshell This phase 2 trial aims to evaluate combinations of hormone therapies, a steroid drug, an immunotherapy drug, and chemotherapy in the treatment of metastatic castration-resistant prostate cancer. The main outcome to be investigated is overall survival (time from treatment until death from any cause). The trial is recruiting in Houston,...
Read More
